Pages that link to "Q37156268"

The following pages link to Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy. (Q37156268):

Displaying 44 items.

• Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance (Q26865927) (← links)
• Suspected methotrexate toxicity from omeprazole: a case review of carboxypeptidase G2 use in a methotrexate-experienced patient with methotrexate toxicity and a review of the literature (Q33401038) (← links)
• Non-infectious chemotherapy-associated acute toxicities during childhood acute lymphoblastic leukemia therapy. (Q33557148) (← links)
• Biliary excretion of imatinib and its active metabolite CGP74588 during severe hepatic dysfunction (Q33908105) (← links)
• High incidence of methotrexate associated renal toxicity in patients with lymphoma: a retrospective analysis (Q33909887) (← links)
• Urinary coproporphyrin I/(I   III) ratio as a surrogate for MRP2 or other transporter activities involved in methotrexate clearance (Q34065294) (← links)
• Erlotinib and pantoprazole: a relevant interaction or not? (Q34457467) (← links)
• Retrospective evaluation of methotrexate elimination when co-administered with proton pump inhibitors (Q34571060) (← links)
• Role of the breast cancer resistance protein (BCRP/ABCG2) in drug transport--an update (Q34871636) (← links)
• Accumulating evidence for a drug-drug interaction between methotrexate and proton pump inhibitors (Q35913249) (← links)
• Non-steroidal anti-inflammatory drugs induce severe hematologic toxicities in lung cancer patients receiving pemetrexed plus carboplatin: A retrospective cohort study (Q36269700) (← links)
• Drug interactions in childhood cancer (Q36898141) (← links)
• Drug interactions may be important risk factors for methotrexate neurotoxicity, particularly in pediatric leukemia patients. (Q37373153) (← links)
• Preventing and Managing Toxicities of High-Dose Methotrexate (Q37496637) (← links)
• The Safety of Appropriate Use of Over-the-Counter Proton Pump Inhibitors: An Evidence-Based Review and Delphi Consensus (Q37709906) (← links)
• Drug-drug interaction profiles of proton pump inhibitors (Q37770556) (← links)
• Drug interactions in metastatic breast cancer (Q37791284) (← links)
• Pharmacokinetic drug-drug interactions with methotrexate in oncology (Q37960131) (← links)
• Interaction of the efflux transporters ABCB1 and ABCG2 with imatinib, nilotinib, and dasatinib. (Q38150978) (← links)
• Adverse drug reactions due to drug-drug interactions with proton pump inhibitors: assessment of systematic reviews with AMSTAR method (Q38658675) (← links)
• Acid-Suppressive Therapy and Risk of Infections: Pros and Cons (Q38865456) (← links)
• Renal Drug Transporters and Drug Interactions (Q39140289) (← links)
• A Comparison of Alkaline Water and Mediterranean Diet vs Proton Pump Inhibition for Treatment of Laryngopharyngeal Reflux (Q40053716) (← links)
• Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia (Q41404243) (← links)
• Evaluation of para-Aminosalicylic Acid as a Substrate of Multiple Solute Carrier Uptake Transporters and Possible Drug Interactions with Nonsteroidal Anti-inflammatory Drugs In Vitro (Q42358808) (← links)
• Glucarpidase rescue in a patient with high-dose methotrexate-induced nephrotoxicity (Q43260573) (← links)
• High-dose methotrexate in adult oncology patients: a case-control study assessing the risk association between drug interactions and methotrexate toxicity (Q43924069) (← links)
• Degree of kinase inhibition achieved in vitro by imatinib and nilotinib is decreased by high levels of ABCB1 but not ABCG2. (Q44639286) (← links)
• Clinical pharmacology in everyday clinical care (Q45142665) (← links)
• Consensus Guideline for Use of Glucarpidase in Patients with High-Dose Methotrexate Induced Acute Kidney Injury and Delayed Methotrexate Clearance (Q46446111) (← links)
• Delayed methotrexate elimination: Incidence, interaction with antacid drugs, and clinical consequences? (Q47250639) (← links)
• Effects of proton pump inhibitors and famotidine on elimination of plasma methotrexate: Evaluation of drug-drug interactions mediated by organic anion transporter 3. (Q48249474) (← links)
• Drug Repositioning of Proton Pump Inhibitors for Enhanced Efficacy and Safety of Cancer Chemotherapy (Q49215917) (← links)
• Effects of Concomitant Medication Use on Gefitinib-Induced Hepatotoxicity (Q49582579) (← links)
• Delayed elimination of high-dose methotrexate and use of carboxypeptidase G2 in pediatric patients during treatment for acute lymphoblastic leukemia. (Q51012681) (← links)
• The prognostic value of serum methotrexate area under curve in elderly primary CNS lymphoma patients (Q51350287) (← links)
• Lansoprazole Exacerbates Pemetrexed-Mediated Hematologic Toxicity by Competitive Inhibition of Renal Basolateral Human Organic Anion Transporter 3. (Q53052634) (← links)
• A Comprehensive Study Demonstrating that P-glycoprotein Function is Directly Affected by Changes in pH: Implications for Intestinal pH and Effects on Drug Absorption (Q57343266) (← links)
• Enantioselective Drug Recognition by Drug Transporters (Q60950304) (← links)
• Potential drug-drug interactions between anti-cancer agents and community pharmacy dispensed drugs (Q84580395) (← links)
• No effects of pantoprazole on the pharmacokinetics of rosuvastatin in healthy subjects (Q89372273) (← links)
• Comedications influence immune infiltration and pathological response to neoadjuvant chemotherapy in breast cancer (Q89457550) (← links)
• Drug interactions in the treatment of rheumatoid arthritis and psoriatic arthritis (Q89689218) (← links)
• Concomitant febuxostat enhances methotrexate-induced hepatotoxicity by inhibiting breast cancer resistance protein (Q92335705) (← links)